Assess whether related-party sales should be backed out of valuation (c59e19)

SITUATION Regulatory-approval critical-path calendar arrived with an HSR second-request rumor. Buy-side QoE lead in a sponsor doing confirmatory after a tight auction still has an evidence gap on whether related-party sales should be backed out of valuation.

DECISION Buy-side QoE lead in a sponsor doing confirmatory after a tight auction must choose Proceed / Reprice / Walk / Hold using regulatory-approval critical-path calendar after an HSR second-request rumor.

HYPOTHESES TO TEST 1. Authorize Proceed now; regulatory-approval critical-path calendar already has the discriminator after an HSR second-request rumor. 2. Keep Reprice in force until regulatory-approval critical-path calendar is completed after an HSR second-request rumor for buy-side QoE lead. 3. Treat regulatory-approval critical-path calendar as Walk because both readings appear after an HSR second-request rumor. 4. Refuse a M&A Due Diligence close: buy-side QoE lead does not have the decision related-party sales should be turns on in regulatory-approval critical-path calendar.

ANALYSIS REQUIRED 1. Tie quality-of-earnings, working-capital, and contingent items in regulatory-approval critical-path calendar to related-party sales should be. 2. Name the document buy-side QoE lead still needs before signing. 3. Test whether an HSR second-request rumor is a diligence gap, a price chip, or a walk-away. 4. For this M&A Due Diligence Separation and Integration file, read regulatory-approval critical-path calendar against an HSR second-request rumor and write the one fact that would move related-party sales should be for buy-side QoE lead.

RECOMMENDATION Choose Proceed / Reprice / Walk / Hold on this M&A Due Diligence / Separation and Integration packet (regulatory-approval critical-path calendar after an HSR second-request rumor). Lead with the M&A Due Diligence option regulatory-approval critical-path calendar can support after an HSR second-request rumor, then the two facts that force it, then the Monday action for buy-side QoE lead in a sponsor doing confirmatory after a tight auction.

COMMAND RETURNS - Bottom-line M&A Due Diligence option on related-party sales should be, then the evidence in regulatory-approval critical-path calendar, then the action for buy-side QoE lead - Hypothesis scorecard against regulatory-approval critical-path calendar: supported / rejected / untestable - Named option among Proceed, Reprice, Walk and the fact that kills the others - Owner and next date for buy-side QoE lead in a sponsor doing confirmatory after a tight auction